Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_4
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 42 (66.7%)
N/A1 (33.3%)

Trials by Status

unknown133%
not_yet_recruiting267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_4

OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation

NCT07496281
unknownphase_4

Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR

NCT05375474
not_yet_recruitingnot_applicable

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

NCT04995159

Clinical Trials (3)

Showing 3 of 3 trials
NCT07496281Phase 4

OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation

Not Yet Recruiting
NCT05375474Phase 4

Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR

Unknown
NCT04995159Not Applicable

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3